Abstract
Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.
Author supplied keywords
Cite
CITATION STYLE
Almagthali, A. G., Alkhaldi, E. H., Alzahrani, A. S., Alghamdi, A. K., Alghamdi, W. Y., & Kabel, A. M. (2019, January 1). Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. Elsevier Ltd. https://doi.org/10.1016/j.dsx.2018.08.012
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
